THERAPEUTICS

Peptide activating macrophages

Immunomodulation provides new therapeutic opportunities through the re-engagement of the immune system against body dysfunction (pathogen infection, oncogenesis, etc.). In particular, macrophage polarization enhances phagocytic capacity as body's first line of protection.

DESCRIPTION*

- Naturally occurring recombinant peptide:
  - Able to activate macrophage's cytotoxic functions against pathogens recognized by type C lectin receptors (bacteria, fungi, yeast, parasites) and tumor cells
  - Enabling the production of pro-inflammatory cytokines
  - Specific activation of macrophages at the tumor site
  - Displaying no direct microbicide activity
  - Depicting no evident cytotoxicity (on human erythrocytes and monocytes)
- *In vitro* and *in vivo* efficacy data on murine model of *Candida albicans*
- *In vitro* efficacy data on lymphoma model and colon cancer cells



Proposed mechanism for macrophage polarization by the peptide

COMPETITIVE ADVANTAGES

- Specific immunomodulation action limiting the rise of resistance
- Potential of synergetic action with existing drugs
- Membrane receptor and signaling pathway identified
- Short sequence peptide:
  - Simple to manufacture
  - Cheap

APPLICATIONS

- Anti-tumor agent
- Anti-infectious agent: bacteria, fungi, yeast, parasites

INTELLECTUAL PROPERTY

- Patent pending

DEVELOPMENT STAGE

- Experimental proof of concept

1	2	3	4	5	6	7	8	9

LABORATORIES

- BTBS, Pharma-Dev and DC2N laboratories

CONTACT

T. +33 (0)5 62 25 50 60
sante@toulouse-tech-transfer.com
www.toulouse-tech-transfer.com

* Technology requiring license rights.